Self-assembled targeted nanoparticles based on transferrin-modified eight-arm-polyethylene glycol–dihydroartemisinin conjugate
Open Access
- 5 July 2016
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 29461
Abstract
Poor delivery of insoluble anticancer drugs has so far precluded their clinical application. In this study, an efficient tumor targeted-nanoparticle delivery system, transferrin-eight-arm-polyethylene glycol–dihydroartemisinin nanoparticles (TF-8arm-PEG-DHA NPs) for the vehiculation of dihydroartemisinin (DHA) was first prepared and evaluated for its targeting efficiency and cytotoxicity in vitro and in vivo to Lewis lung carcinoma (LLC) cells, which overexpress transferrin receptors (TFRs). The synthesized TF-8arm-PEG–DHA NPs had high solubility (~102 fold of free DHA), relatively high drug loading (~10 wt% DHA), long circulating half-life and moderate particle size (~147 nm). The in vitro cytotoxicity and in vivo tumor growth inhibition studies in LLC-tumor bearing mice confirmed the enhanced efficacy of TF-modified 8arm-PEG-DHA NPs compared to free DHA and non-modified 8arm-PEG-DHA NPs. All these results together supported that the formulation developed in this work exhibited great potential as an effective tumor targeting delivery system for insoluble anticancer drugs.Keywords
This publication has 42 references indexed in Scilit:
- Determination of carbohydrate‐deficient transferrin in human serum by capillary zone electrophoresis: Evaluation of assay performance and quality assurance over a 10‐year period in the routine arenaElectrophoresis, 2013
- Interpretation of protein quantitation using the Bradford assay: Comparison with two calculation modelsAnalytical Biochemistry, 2013
- Vitamin B12 loaded polycaprolactone nanofibers: A novel transdermal route for the water soluble energy supplement deliveryInternational Journal of Pharmaceutics, 2013
- Hydrogel drug delivery system with predictable and tunable drug release and degradation ratesProceedings of the National Academy of Sciences, 2013
- The Complex Role of Multivalency in Nanoparticles Targeting the Transferrin Receptor for Cancer TherapiesJournal of the American Chemical Society, 2010
- Dihydroartemisinin inhibits growth of pancreatic cancer cells in vitro and in vivoAnti-Cancer Drugs, 2009
- Experimental Therapy of Hepatoma with Artemisinin and Its Derivatives: In vitro and In vivo Activity, Chemosensitization, and Mechanisms of ActionClinical Cancer Research, 2008
- Antimalarial Drug Toxicity: A ReviewChemotherapy, 2007
- Efficient gene delivery targeted to the brain using a transferrin‐conjugated polyethyleneglycol‐modified polyamidoamine dendrimerThe FASEB Journal, 2007
- Effects of artemisinin-tagged holotransferrin on cancer cellsLife Sciences, 2005